Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
Ars Technica1 min read
2 stories
Markers released top-line results today after previously reporting the trial succeeded.
HONG KONG -- Moderna, the U.S. biotech company known for developing an mRNA vaccine against COVID-19, is exploring partnerships in China as it broaden
Showing 2 of 2 stories
You're all caught up.
Get the top AI news and tools straight to your inbox every week.
Weekly · AI news
Join 15,000+ AI enthusiasts